307 related articles for article (PubMed ID: 10473885)
1. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
Saleh AW; Hillen HF; Duits AJ
Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
3. Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy.
Saleh AW; Duits AJ; Gerbers A; de Vries C; Hillen HF
Acta Haematol; 1998; 100(1):26-31. PubMed ID: 9691143
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.
Benkerrou M; Delarche C; Brahimi L; Fay M; Vilmer E; Elion J; Gougerot-Pocidalo MA; Elbim C
Blood; 2002 Apr; 99(7):2297-303. PubMed ID: 11895759
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
7. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
8. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
Barbu EA; Dominical VM; Mendelsohn L; Thein SL
PLoS One; 2019; 14(12):e0226583. PubMed ID: 31869367
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
Conran N; Fattori A; Saad ST; Costa FF
Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
[TBL] [Abstract][Full Text] [Related]
10. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
[TBL] [Abstract][Full Text] [Related]
12. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients.
Conran N; Oresco-Santos C; Acosta HC; Fattori A; Saad ST; Costa FF
Br J Haematol; 2004 Feb; 124(4):547-54. PubMed ID: 14984506
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells.
Brun M; Bourdoulous S; Couraud PO; Elion J; Krishnamoorthy R; Lapoumeroulie C
Pharmacogenomics J; 2003; 3(4):215-26. PubMed ID: 12931135
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
Keikhaei B; Yousefi H; Bahadoram M
Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
[TBL] [Abstract][Full Text] [Related]
15. Minimal doses of hydroxyurea for sickle cell disease.
Lima CS; Arruda VR; Costa FF; Saad ST
Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721
[TBL] [Abstract][Full Text] [Related]
16. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
17. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
[TBL] [Abstract][Full Text] [Related]
19. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
[TBL] [Abstract][Full Text] [Related]
20. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]